NLS phase III

Danish Zealand has announced that a milestone has been achieved in the advance of Lixilan towards start of phase III development in the 1st quarter of 2014. The milestone relates to the approval of the first phase III study protocol for Lixilan by a health authority, triggering a USD 15 million payment to Zealand. Lixisenatide […]

The Swedish company has announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients. “Based on these encouraging data with the high cure rates seen in […]

AstraZeneca has announced the first patient randomized in a phase III clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive. In 2003, Array BioPharma invented and licensed the worldwide rights to develop and commercialize […]

NeuroVive has announced that more than 800 patients are to be included in their ongoing European Phase III study with CicloMulsion for treatment of reperfusion injury following a heart attack. The study is going according to the initial plan, says the company, and at the moment there are 44 active centers involved, in France, Belgium […]

The company has announced enrollment of the first patient in the Phase III clinical programme for olaparib. The company’s oral poly ADP ribose polymerase (PARP) inhibitor is being investigated for the treatment of BRCA mutated ovarian cancer. The SOLO (Study of OLaparib in Ovarian cancer) programme is designed to determine the benefit, by progression free […]